Dear Reader,

As we reach the final issue of *Drugs in R&D* for 2012, we hope you have found the articles published throughout the year to be interesting and informative. The editors and publishing staff have appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with topical issues in the field of research and development in 2013.

Following the acquisition of the Adis journals at the end of last year by Springer Science+Business Media, we have been working to transition the production and fulfillment of the Adis journals into Springer processes. This integration will be complete by the end of 2012, such that production and delivery of all Adis journals will be fully transitioned for the first issues of 2013. Adis journal content will be available on a new and improved online platform.

We are pleased that Springer has decided to keep the Adis brand and recognizes the core values that the brand represents. We are confident that the association with Springer will lead to increased awareness and usage of Adis content, further driving impact factors and recognition. Collectively, we feel that the future for Adis looks bright, and we are happy with the acquisition by Springer.

The high quality of Adis Journals was acknowledged in the new ISI impact factors for 2011, with the majority of our titles making gains over 2010. The most impressive gains were made by *Clinical Pharmacokinetics* (5.398), with a 19.6% increase, *Drugs* (4.226), which increased by 13%, and *Clinical Drug Investigation* (1.822), an increase of 12.3% over 2010. Two of our journals received their first impact factors in 2011 --- *Pediatric Drugs*, with an impact factor of 1.786, and *The Patient* (0.571).

We would like to say a big thank you to all of the authors who have contributed articles to *Drugs in R&D* within the last 12 months. Without their hard work and diligence, we would not have been able to publish the journal. The quality of published articles also reflects the significant time and effort dedicated by the peer reviewers, who ensure that we continue to publish content of the highest possible standard. In addition to the members of our Honorary Editorial Board, we would like to thank the following individuals, who acted as referees for articles in *Drugs in R&D* in 2012: *Albert Adell*, Spain*Ali Alikhan*, USA*Robert J. Amato*, USA*Soo Kyung Bae*, Republic of Korea*Luis Bahamondes*, Brazil*Bernard Bannwarth*, France*Marcelo C. Bertolami*, Brazil*Joseph M. Blondeau*, Canada*Nichola Boyle*, Australia*Peter Bramlage*, Germany*Yong Chen*, USA*Victor Chuang*, Australia*Daniel F. Connor*, USA*Gilberto De Nucci*, Brazil*Sheila A. Doggrell*, Australia*Santiago Ewig*, Germany*David N. Franz*, USA*David J. Greenblatt*, USA*Ganesh V. Halade*, USA*Sanjeev Handa*, India*Klaas A. Hartholt*, the Netherlands*Daniel E. Hilleman*, USA*Gabor Hollo*, Hungary*Li Huafang*, China*Atsuko A. Inoue*, Japan*Makoto Ishikawa*, Japan*Hartmut Jaeschke*, USA*Joetta M. Juenke*, USA*Menelaos Karanikolas*, Greece*Kiyoshi Kikuchi*, Japan*Gideon Koren*, Canada*Paul A. Lapchak*, USA*Leonard Liebes*, USA*Charles L. Loprinzi*, USA*Gianluca Manni*, Italy*Robert Mathie*, UK*Andrew J. McLachlan*, Australia*Andrei V. Medvedovici*, Romania*Marco Montillo*, Italy*F. Marcel Musteata*, USA*Samar Muwakkit*, Lebanon*Taizen Nakase*, Japan*Hiroaki Naritomi*, Japan*Michinori Ogura*, Japan*Muge G. Ozden*, Turkey*Girolamo Pelaia*, Italy*Rita Pichardo*, USA*Charalampos Pierrakos*, Belgium*Simon W. Rabkin*, Canada*Alex Rawlinson*, UK*Claire Relton*, UK*James L. Roerig*, USA*Menachem Rottem*, Israel*Brian B.H. Rowe*, Canada*Barry Rumack*, USA*A. Oliver Sartor*, USA*Bancha Satirapoj*, Thailand*Rashmi R. Shah*, UK*Manuel Sosa*, Spain*Carlos Sostres*, Spain*Motohiro Tamiya*, Japan*Joel Tarning*, Thailand*Michael E. Thase*, USA*Sadao Tokimasa*, Japan*Chaitra S. Ujjani*, USA*Giuseppe Visani*, Italy*Mari Wataya-Kaneda*, Japan*Ping Wei*, China*Paul Welsh*, UK*William N. William Jr.*, USA*Johannes Wohlrab*, Germany*Cory Yamashita*, Canada*Takashi Yamashita*, USA*Abdel N. Zaid*, Palestinian Territory*Xiangjian Zhang*, China*Yan Zhang*, USA

We look forward to your continued support of the journal in 2013 and to bringing you first-class content from around the globe.

Best wishes from the staff of *Drugs in R&D* and all at Adis Publications.
